| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555048 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) | |
| US8828440 | PACIRA PHARMS INC | Corticosteroids for the treatment of joint pain |
Aug, 2031
(7 years from now) | |
Zilretta is owned by Pacira Pharms Inc.
Zilretta contains Triamcinolone Acetonide.
Zilretta has a total of 2 drug patents out of which 0 drug patents have expired.
Zilretta was authorised for market use on 06 October, 2017.
Zilretta is available in for suspension, extended release;intra-articular dosage forms.
Zilretta can be used as method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide.
The generics of Zilretta are possible to be released after 04 August, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 06, 2020 |
Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient
Market Authorisation Date: 06 October, 2017
Treatment: Method of treating pain or inflammation with an injectable controlled or sustained release formulation of triamcinolone acetonide
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR
ZILRETTA family patents
